biosensors | GenomeWeb

biosensors

A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.

The company's core technology involves the use of cultured cells as biosensors to detect expression levels of genes associated with the disease.

The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research. 

British biotechnology firm QuantuMDx last week announced an agreement with the Genome Institute of Singapore that will see the partners develop a genetic test specific to Asian populations on QuantuMDx's nanowire array-based platform.

NEW YORK (GenomeWeb News) – Mediomics has reeled in a $997,251 grant from the National Cancer Institute to continue developing technologies for monitoring the titer and quality of recombinant biologics, the company said today.

Attana recently announced that it has been certified according to the International Organization for Standardization's 9001:2008 quality management systems standard.

Biomagnetics Diagnostics intends to develop a handheld, integrated optical biosensor for rapid diagnosis of HIV/AIDS, malaria, tuberculosis, and other pathogens.

STC.UNM, the technology-transfer arm for UNM, was lead institution on the agreement, under which Adaptive Methods may obtain an exclusive license to manufacture and sell a variety of products incorporating the biosensor technology.

Tech Transfer Tidbits

Premium

Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …

IP Roundup

Premium

SRU Biosystems, Samsung Electronics, Sandia Corp., Agilent Technologies, BioArray Solutions, Fluidigm

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.